Day: May 18, 2020

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations – Europe. His mission will be to ensure execution upon Technical Operation milestones in process development, analytical development, external supply, and the GMP Paris manufacturing facility that support the development and production of Cellectis proprietary product candidates.  Dr. Bertea is based in the Cellectis Paris office and reports to Bill Monteith, Executive Vice President, Technical Operations.Dr. Bertea joined from CellforCure where he was General Manager and Site Head upon...

NEW YORK, 18 mai 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), une société biopharmaceutique de stade clinique spécialisée dans le développement d’immunothérapies fondées sur des cellules CAR-T allogéniques ingénierées (UCART), a annoncé la nomination de Leopold Bertea, Ph.D., au poste de Vice-président sénior des Opérations Techniques – Europe. Sa mission sera de garantir l’atteinte des objectifs du département des Opérations Techniques, qui incluent le développement de procédés, le développement analytique, l’approvisionnement externe et le site de production GMP Paris qui soutient le développement et la production des produits candidats propriétaires de Cellectis.  Le Dr Bertea est basé au siège social de Cellectis à Paris et est rattaché à Bill Monteith, Vice-président exécutif des Opérations...

BETHESDA, Md., May 18, 2020 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ: LQDT), a global solution provider in the reverse supply chain with the world’s largest marketplace for business surplus, is pleased to highlight its current auction for construction machinery located in Round Rock, TX through its newest online auction marketplace, www.AllSurplus.com. The auction includes heavy equipment from Caterpillar, John Deere and Volvo and closes on May 27, 2020.“The construction equipment assets for sale in Round Rock provide an opportunity for buyers to invest in equipment with a lower upfront cost than purchasing new machines,” said Michael Smith, senior director heavy equipment sales for Liquidity Services. “By purchasing previously owned assets, can speed the time to productivity, which is critical in today’s environment.”Featured...

HAMILTON, BERMUDA, May 18, 2020 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) announced that, in connection with the effect of the previously announced cash dividend of $0.35 per share of common stock to be paid on May 26, 2020 to stockholders of record as of the close of business on May 19, 2020, the conversion price (the “Conversion Price”) of the Company’s 4.5% Convertible Senior Notes due 2021 (the “Notes”) was adjusted, effective May 18, 2020. The Conversion Price was adjusted from $5.6468 per share to $5.3470 per share, which represents a conversion rate of approximately 187.0208 shares of common stock per $1,000 principal amount of Notes. A detailed calculation of the adjustment to the Conversion Price can be found in the “Investor Relations” section of our website www.dhtankers.com.About DHT Holdings, Inc.DHT is an independent...

The board of directors of IDEX Biometrics ASA resolved on 18 May 2020 to issue 357,300 incentive subscription rights to employees in the IDEX group. The grant was made under the company’s 2020 incentive subscription rights plan as resolved at the annual general meeting on 15 May 2020. The exercise price of the subscription rights is NOK 1.63 per share. The subscription rights vest by 25% per year over four years and expire on 15 May 2025. Following the grant there are 57,453,193 subscription rights outstanding in IDEX.For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 918 00186Derek D’Antilio, Chief financial OfficerE-mail: derek.dantilio@idexbiometrics.comTel: +1 197 827 31344About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider...

MALVERN, Pa., May 18, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced today that it will host a virtual Key Opinion Leader (KOL) event on cisplatin-induced chronic kidney disease on Friday, May 22, 2020, from 10 a.m. to 11 a.m. EDT.The event will feature a panel discussion regarding the clinical challenges of nephrotoxicity of platinum-based chemotherapy (cisplatin) in the treatment of patients with head and neck cancer, and a summary of the preliminary findings from a retrospective analysis of Phase 2b trial data in patients with head and neck cancer and the potential role of avasopasem manganese (GC4419) in this...

– Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected in the second quarter of calendar year 2020– New Drug Application (NDA) submitted for relugolix monotherapy tablet for men with advanced prostate cancer, with castration resistance-free survival results expected in the third quarter of calendar year 2020– Marketing Authorization Application for relugolix combination tablet for women with uterine fibroids submitted and currently under evaluation by the European Medicines Agency, with NDA submission expected in May 2020– Strategic partnership with Gedeon Richter formed to accelerate the potential launch of relugolix combination tablet for uterine fibroids and endometriosis in certain territories outside...

PHOENIX, May 18, 2020 (GLOBE NEWSWIRE) — Sprouts Farmers Market, Inc. (Nasdaq: SFM) today announced that Jack Sinclair, Chief Executive Officer, and Denise Paulonis, Chief Financial Officer, will present at the Bernstein’s 36th Annual Strategic Decisions Virtual Conference. The fireside chat and strategy update will begin at 1:30 pm EDT on May 27, 2020.A live webcast of the fireside chat will be available on the Investor Relations section of the Company’s website at investors.sprouts.com. A replay will be archived and available at the same location.About Sprouts Farmers MarketSprouts Farmers Market, Inc., one of the fastest-growing retailers in the country, has made healthy living accessible to shoppers for nearly two decades by offering affordable, fresh, natural and organic products. True to its farmers market heritage, Sprouts...

 Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected in the second half of 2020Conference Call and Webcast Scheduled Today at 4:30 PM ETWARMINSTER, Pa., May 18, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound. William Collier, President and Chief Executive Officer of Arbutus, stated, “These new data...

           Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, including Granisetron, Zolmitriptan and Dihydroergotamine  SOUTH SAN FRANCISCO, Calif., May 18, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that two abstracts and scientific presentations from its STS101 (dihydroergotamine (DHE) nasal powder) development program for the acute treatment of migraine were selected for presentation on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Virtual Platform.  The 2020 AAN Science Highlights Virtual Platform...